AlloCure Inc.’s Investigational Treatment for Acute Kidney Injury Receives Fast Track Designation by FDA

Published: Jan 05, 2012

BURLINGTON, Mass.--(BUSINESS WIRE)--AlloCure, Inc., a clinical stage biotechnology company focused on the treatment of kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AC607, the company’s investigational treatment for acute kidney injury (AKI).

Back to news